This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marchand, L. L. Articles by Wilkens, L. R. Search for Related Content PubMed PubMed Citation Articles by Marchand, L. L. Articles by Wilkens, L. R.

Genetic and Dietary Predictors of CYP2E1 Activity: A Phenotyping Study in Hawaii Japanese Using Chlorzoxazone¹

Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii 96813 [L. L. M., L. R. W.], and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232 [G. R. W.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cytochrome P4502E1 (CYP2E1) is considered to play an important role in the metabolic activation of procarcinogens such as N-nitrosoamines and low molecular weight organic compounds. An RsaI polymorphism is present in the 5'-flanking region of the CYP2E1 gene, which could possibly affect its transcription. However, the relationship between genotype and the phenotypic catalytic activity of the enzyme has not been defined. Also, the effects in humans of specific dietary factors, other than ethanol, which have been shown in animal and in vitro studies to modulate CYP2E1 activity, are unknown. Accordingly, the CYP2E1-mediated metabolism of chlorzoxazone to its 6-hydroxy metabolite was investigated in 50 healthy Japanese of both sexes in Hawaii. The oral clearance of the in vivo probe, the trait measure of CYP2E1 activity, was smaller than that reported in European-Americans. Significantly, after adjustment for age and sex, the oral clearance of chlorzoxazone decreased with the number of variant c2 alleles, and its mean in the c2/c2 genotype (147 ml/min) was statistically lower (P 0.05) than that for either the homozygous wild-type (238 ml/min) or the heterozygote (201 ml/min) genotypes. Stepwise multiple regression analysis indicated that body weight was a major contributor to the interindividual variability in the oral clearance of chlorzoxazone, accounting for 43% of the variance. Consumption of lettuce, broccoli, and black tea explained additional components of the variability (7, 5, and 6%, respectively), as did medication use (3%), age (4%), and CYP2E1 genotype (5%). Overall, 73% of the variance could be accounted for by these variables. Body weight, lettuce, and use of medications were associated with increased CYP2E1 activity, and the other covariates were associated with reduced enzyme function. Because of the role that CYP2E1 plays in procarcinogen activation, especially of N-nitrosamines involved in lung cancer, the identified factors may account in part for observed differences in individual susceptibility to disease and may also have implications for cancer prevention.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Among the various human cytochrome P450s, CYP2E1³ is of particular interest because of its involvement in the metabolic activation of many carcinogenic and toxic chemicals, such as environmental N-nitrosamines present in tobacco smoke and the diet, which are considered to play a significant role in the induction of certain types of cancer (1, 2, 3) , butadiene, vinyl chloride, benzene and many of its derivatives, and halocarbons (4 , 5) . CYP2E1 is also involved in the oxidation of ethanol (6) , as well as the production of reactive oxygen species that may initiate lipid peroxidation (5) .

Considerable interindividual variability in human CYP2E1 activity has been observed both in vitro using liver microsomes (7 , 8) and, to a somewhat lesser extent, in vivo based on the 6-hydroxylation of chlorzoxazone as a probe (9 , 10) . Both pathophysiological determinants, such as obesity (11) , fasting (11) , liver dysfunction (12) , and environmental factors including induction by ethanol (10) and inhibition by drugs, such as disulfiram (13) and chlormethiazole (14 , 15) , or by dietary isothiocyanates (16) , have been shown to modulate CYP2E1 activity and contribute to this variance. In addition, genetic factors may also be involved because RFLPs exist in the 5'-flanking region (RsaI) and in intron 6 (DraI) of the CYP2E1 gene (17) . Determination of putative relationships between these (partially linked) variant alleles and the resulting phenotype have, however, been largely limited both in vitro (18 , 19) and in vivo (9 , 20 , 21) to Caucasian subjects, where the rarity of the variant alleles makes studies of sufficient statistical power difficult. Nevertheless, there is suggestive evidence that the variant c2 allele of the RsaI polymorphism may be associated with reduced CYP2E1 activity (18, 19, 20, 21) , despite the fact that in vitro this allele was found to increase expression of a reporter gene construct (22 , 23) .

The importance of variability in CYP2E1 activity lies in its possible relationship to individual susceptibility to the carcinogenic and/or toxic effect of its substrates following activation by the enzyme. For example, the lower CYP2E1 level in Japanese men (21) could be a contributing factor to the reduced risk of lung cancer in this population compared with Caucasians with a similar smoking history (24 , 25) . Similarly, it may be a factor in explaining the lower lung cancer risk in individuals carrying the RsaI or DraI variant allele compared with those with a wild-type genotype, observed among Japanese, Hawaiians, and African-Americans (26, 27, 28, 29) .

To further explore the genotype:phenotype relationship for CYP2E1, a study was undertaken in healthy men and women of pure Japanese ancestry residing in Hawaii. In addition, possible relationships between CYP2E1 activity and certain dietary constituents were also investigated.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
The clinical protocol used in this study was reviewed and approved by the Committee on Human Studies of the University of Hawaii and by the Institutional Review Board of the Kapiolani Health Research Institute. Written informed consent was also obtained from all participants.

About half of the 50 subjects studied were identified from individuals who had participated as controls in case-control studies of lung and colorectal cancers in Hawaii (29 , 30) . The remainder were separately recruited through newspaper advertisement. Potential subjects were genotyped for the CYP2E1 RsaI polymorphism to recruit an approximately equal number of individuals of each genotype (c1/c1, c1/c2, and c2/c2). All subjects were of pure Japanese ancestry (i.e., with four Japanese grandparents) and healthy on the basis of medical history and routine laboratory tests including those indicative of renal and hepatic function. None of the individuals smoked tobacco products or regularly drank ethanol, and the female subjects were not pregnant. Subjects were instructed to abstain from ethanol, acetaminophen, and any other nonessential medications during the week prior to the phenotyping and also to keep a record of all foods, medications, and vitamin supplements taken during the last 3 of the 7 prestudy days.

After an overnight fast, 250 mg of chlorzoxazone (PAR Pharmacy, New York, NY) was administered p.o., and fasting was maintained for an additional 3 h. Venous blood samples were obtained using heparin as an anticoagulant from an arm vein at 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 h after drug administration. Plasma was separated and stored at -80°C until analysis. Urine was also collected during the 0–4- and 4–8-h periods and stored at -80°C. Chlorzoxazone and its 6-hydroxy metabolite in plasma and urine were determined by a reverse-phase HPLC procedure, subsequent to appropriate hydrolysis of conjugated metabolite, as described previously (11) . These assays were done blinded as to the subject’s genotype. Quality control measurements, during the period that the samples were analyzed, indicated an interday coefficient of variation <12% for both chlorzoxazone and its 6-hydroxy metabolite at a concentration of 1 µg/ml. The area under the plasma concentration-time curve for each compound was determined trapezoidally and extrapolated to infinity using a log-linear estimation of the terminal rate constant. The oral clearance of chlorzoxazone was determined from the ratio of the administered dose to the area under the curve of the drug.

Subjects were genotyped for the CYP2E1 RsaI polymorphism after isolation of DNA from peripheral lymphocytes by using the primers 5'-TTCATTCTGTCTTCTAACTGG-3' and 5'-CCAGTCGAGTCTACATTGTCA-3' to PCR amplify a region containing a base substitution in the 5' flanking region of the gene (9 , 29) . Cycling conditions included an initial denaturation at 94°C for 4 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min, extension at 72°C for 1 min, and final annealing and extension at 55°C for 1 min and 72°C for 7 min. RsaI digestion of the PCR products and electrophoresis on an agarose gel identified the homozygous wild-type genotype (c1/c1; 360- and 50-bp fragments), homozygous variant genotype (c2/c2; single 410-bp fragment), and heterozygous c1/c2 genotype (all three fragments).

Dietary intakes, averaged over the 3 days of record, were used to investigate possible effects of diet on the oral clearance of chlorzoxazone. The food composition data used to compute nutrient intake were primarily based on the United States Department of Agriculture’s nutrient database (31) and were supplemented with data from other research and commercial publications. Nutrient intakes were adjusted for calories by the method of residuals (32) . These food intake and nutrient values, along with the pharmacokinetic parameters of chlorzoxazone, were log-transformed for their distributions to approximate normality.

Analysis of covariance was used to compare means of continuous variables among the CYP2E1 genotypes, adjusting for covariates. The unadjusted results comparing oral clearance across genotype were confirmed by a nonparametric method (Mann-Whitney U test). A forward stepwise procedure was used to determine the importance of each variable in explaining the variance in the oral clearance of chlorzoxazone after controlling for other covariates. A variable was retained in the model when the P for the association of the variable with the independent variable was <0.05. The explanatory variables selected for potential inclusion in the regression were those shown previously to affect levels of CYP2E1 or other xenobiotic-metabolizing enzymes and/or to be associated with cancer risk (Table 4 footnote). These variables have the potential to not only increase the background variability in CYP2E1 activity but also to act as confounders of an association of CYP2E1-mediated activation with cancer. Genotype was parameterized by two dummy variables representing the heterozygous and homozygous variant genotypes. The procedure was repeated with genotype entered as number of variant alleles to test for a genetic trend. The model assumptions were met, as verified by residual analysis. Pearson’s correlation coefficients were computed to investigate the relationships between the oral clearance and continuous variables of chlorzoxazone, such as age and weight.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

View larger version (13K): [in this window] [in a new window]   Fig. 1. Mean plasma concentration-time curves of chlorzoxazone after an oral 250-mg dose according to genotype.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The disposition of chlorzoxazone in healthy subjects has been well described (9 , 10 , 21 , 33) , as have factors affecting its metabolism (10, 11, 12, 13, 14, 15 , 34) . Available evidence in humans indicates that in vivo the 6-hydroxylation of the drug is predominantly, if not exclusively, mediated by CYP2E1, and that this pathway of metabolism is the major determinant of the clearance of the drug after oral administration (9) . Accordingly, observed differences in the oral clearance of chlorzoxazone reflect overall CYP2E1 activity within the body. On the basis of this in vivo probe approach, the interindividual variability of CYP2E1 in young, medication-free, healthy Caucasians has been shown to be unimodally distributed with a 4- to 5-fold range in activity (9) . The present findings in healthy subjects of Japanese ancestry residing in Hawaii are generally consistent with this magnitude of variability. Moreover, the clearance of the in vivo probe in these subjects was lower than that reported in Caucasians (9) , which is similar to an earlier finding that the oral clearance of chlorzoxazone was 30–40% lower in Japanese men residing in Tokyo than in European-Americans, even after taking into account differences in body size (21) . Because environmental factors are quite distinct between Japan and Hawaii, and in particular, subjects in the present study consumed a "western" diet, this suggests that this difference between the two ethnic groups probably has a genetic basis.

It was also of interest that the 25% lower oral clearance of chlorzoxazone found for Japanese women compared with men was of similar magnitude as to the sex difference observed previously in Caucasians (9 , 11) . However, in our data, this sex difference was explained by body weight. Indeed, this factor was identified as a major predictor of the oral clearance of chlorzoxazone, supporting the notion that CYP2E1 activity is regulated in some fashion by body mass. This association could simply reflect a relationship with liver size (35) ; alternatively, it may be indicative of a more fundamental mechanism involving the regulation of CYP2E1 by nutritional and physiological factors (5) . In this regard, it is noteworthy that dietary fat intake and its composition, despite being inducers of CYP2E1 in animals (36 , 37) , were not identified as statistically significant covariates in the regression analysis.

The identification of RFLPs in the CYP2E1 gene (17) has resulted in considerable speculation as to their possible functional significance and possible involvement in individual susceptibility to disease including lung cancer. Efforts to address such issues have been complicated by the fact that the frequencies of these polymorphisms vary substantially according to the racial background of the population. In the case of the RsaI point mutation in the 5'-flanking region, the c2 allelic variant is relative rare (2–8%) in Caucasian and African-American populations (38 , 39) . As a result, association studies of this polymorphic locus in these groups have had low statistical power (27 , 40, 41, 42, 43, 44) . The c2 mutation is more prevalent (24%) in Japanese and Taiwanese (38 , 39) , and investigations in these populations have detected significant associations, with lung cancer for example (26 , 29) .

Similar power considerations also apply to attempts to relate genotype to phenotype on the basis of the 6-hydroxylation of chlorzoxazone. For example, in vitro studies of CYP2E1 activity in human liver microsomes (18 , 19) have collectively included samples from 134 wild-type homozygotes, 16 heterozygotes, and only 1 homozygous variant individual. In general, no difference was observed between c1/c1 and c1/c2 microsomal activity; however, the single c2/c2 sample had a V_max of 50% that of all of the microsomes studied, whereas the K_ms exhibited no intergenotypic differences (19) . In vivo studies in uninduced individuals (9 , 20 , 21) have had a similar genotypic frequency distributions (154 c1/c1, 8 c1/c1, and 1 c2/c2) but are, in general, consistent with the in vitro findings, i.e., no statistical difference was found between homozygous wild-type and heterozygote groups, although the suggestion of lower activity was present for the latter; again, a substantially reduced chlorzoxazone 6-hydroxylation was observed in the single c2/c2 individual (20) . Additionally, patients with the c2 allele appeared to have less induction of CYP2E1 than wild-type individuals after ethanol administration (20) .

The present study in Hawaii Japanese was designed to overcome the above sampling problems by specifically recruiting individuals of known genotype so that all three genotypic groups would be adequately represented. Although no significant difference was observed in the oral clearance of chlorzoxazone between homozygous wild-type and heterozygous groups, a highly significant lower value was found in the homozygous variant group. Moreover, the stepwise regression analysis showed a statistically significant inverse relationship between CYP2E1 activity and the number of variant RsaI alleles (P for trend = 0.02), after adjusting for the other covariates. However, it should be noted that the magnitude of the difference between the two homozygous groups was modest (<2-fold). Nevertheless, a number of studies have suggested that the risk of developing cancers of the lung, liver, and esophagus, for example, is reduced in individuals who have a c2 allele (27 , 29 , 41 , 43, 44, 45) , consistent with a reduced level of procarcinogen activation by CYP2E1. Other studies, however, have not found such an association (40 , 46 , 47) , which probably reflects power limitations and possibly the fact that other contributors of CYP2E1 variability were not adjusted for in these studies. Also, it should be noted that the CYP2E1 genotype:phenotype relationship determined in human hepatic tissue or in vivo is contrary to that suggested by in vitro 5'-flanking region deletion studies (22 , 23) . Such gene experiments have suggested that the c2 allele is associated with increased transcriptional activation of the CYP2E1 gene. The explanation for this clear discordancy is unknown; however, it does emphasize the need for caution in extrapolating functional genomic data to the in vivo situation. Finally, the lower catalytic activity associated with the c2 allele and the higher frequency of this allele in Japanese compared with Caucasians provide a mechanistic explanation, along with body size, for the ethnic difference in the oral clearance of chlorzoxazone observed in representative groups from these two populations (9) .

An inverse relationship between fruit and vegetable consumption and a reduced risk of developing various forms of cancer is now well established (48) . Mechanisms by which such protection could arise are several (49) , but in many cases, modulation of the activity of xenobiotic-metabolizing enzymes has been implicated, in particular the inhibition of enzymes involved in procarcinogen activation (50) . Moreover, the effects of specific dietary components on CYP isoforms have been investigated extensively in vitro and in animals. For example, isothiocyanate-containing (Brassica) cruciferous vegetables, including brussels sprouts, broccoli, Chinese cabbage, watercress, and their putative active constituents, have been shown to inhibit CYP2E1 (50, 51, 52) . Similar data have been reported for garlic (Allium sativa) and its preparations that contain various organo-sulfur compounds (53 , 54) , and for components of both green and black tea, especially epigallocatechin-3-gallate (55) . Data to substantiate whether typical dietary amounts of such compounds produce similar effects in humans are, however, more limited. Watercress has recently been reported to be a potent inhibitor of chlorzoxazone 6-hydroxylation (16) , and a 12-day feeding study found that 500 g/day of broccoli resulted in a mean 19% reduction in CYP2E1 activity, although this difference was not statistically significant (56) . In our study, broccoli and black tea consumption were found to be significant predictors of lower oral clearance of chlorzoxazone. It is unclear why only black tea and not green tea, which was also consumed by many of the study subjects, was associated with reduced CYP2E1 activity. Interestingly, lettuce intake was associated with increased chlorzoxazone 6-hydroxylation; however, the possible mechanism for such apparent induction is unknown. Ethanol intake was not found to be a contributing factor because, by design, the study subjects had not consumed any significant amount of alcohol during the 7 days prior to phenotyping, a period of time sufficient to remove any ethanol induction of CYP2E1 (10 , 20) .

Because of the relatively large number of environmental variables considered in our analysis, some of the statistically significant associations may have occurred by chance. Consequently, and also because of the cross-sectional design, the observed dietary relationships require confirmation prospectively, preferably by intervention studies. Finally, it should be emphasized that, although the overall genotypic distribution of the study subjects was purposely different from that in the general population, the dietary findings should be generalizable to the general population because similar relationships were observed when the analyses were stratified according to genotype.

In summary, this is the first study to demonstrate a genetic component in the interindividual variability in CYP2E1 activity in humans. Additionally, the findings have identified body weight as an important determinant of the variance and suggest that certain dietary constituents may up- or down-regulate the activity of the enzyme. Because of the role that CYP2E1 is considered to play in the activation of procarcinogens, especially N-nitrosamines involved in lung cancer, such factors may account in part for differences in individual susceptibility to disease. Furthermore, the dietary findings may have implications for cancer prevention.

	Acknowledgments

 
We wish thank Dr. David Easa and the staff of the Clinical Research Center at Kapiolani Medical Center in Honolulu for their help in recruiting participants and performing the phenotyping studies.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by USPHS Grants CA55874, CA60987, CA76020, GM31304, and RR/AI11091.

² To whom requests for reprints should be addressed, at Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Suite 407, Honolulu, HI 96813.

³ The abbreviation used is: CYP2E1, cytochrome P-450 2E1.

Received 11/30/98; revised 3/ 8/99; accepted 3/17/99.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Yang C. S., Yoo J. S. H., Ishizaki H., Hong J. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab. Disp., 22: 147-159, 1990.
2. Yamazaki H., Inui Y., Yun C. H., Guengerich F. P., Shimada T. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis (Lond.), 13: 1789-1794, 1992.[Abstract/Free Full Text]
3. Hecht S. S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Res. Toxicol., 11: 560-603, 1998.
4. Guengerich F. P, Kim D-H., Iwasaki M. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4: 168-179, 1991.[Medline]
5. Ronis M. J. J., Lindros K. O., Ingelman-Sundberg M. The CYP2E1 subfamily Ioannides C. eds. . Cytochromes P450: Metabolic and Toxicological Agents, : 212-239, CRC Press Boca Raton FL 1996.
6. Lieber C. S. Mechanisms of ethanol-drug nutrition interactions. Clin. Toxicol., 32: 631-681, 1994.[Medline]
7. Yoo J. S. H., Guengerich F. P., Yang C. S. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res., 48: 1499-1504, 1988.[Abstract/Free Full Text]
8. Hunt C. M., Strater S., Stave E. M. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem. Pharmacol., 10: 1666-1669, 1990.
9. Kim R. B., O’Shea D., Wilkinson G. R. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther., 57: 645-655, 1995.[Medline]
10. Girre C., Lucas D., Hispard E., Menez C., Dally S., Menez J-F. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol., 47: 1503-1508, 1994.[Medline]
11. O’Shea D., Davis S. N., Kim R. B., Wilkinson G. R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin. Pharmacol. Ther., 56: 359-367, 1994.[Medline]
12. Dilger K., Metzler J., Bode J. C., Klotz U. CYP2E1 activity in patients with alcoholic liver disease. J. Hepatol., 27: 1009-1014, 1997.[Medline]
13. Kharasch E. D., Thummel K. E., Mhyre J., Lillibridge J. H. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin. Pharmacol. Ther., 53: 643-650, 1993.[Medline]
14. Gerhardt A. C., Lucas D., Ménez J-F., Seitz H. K. Chlormethiazole inhibition of cytochrome P4502E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology, 26: 957-961, 1997.[Medline]
15. Eap C. B., Schnyder C., Besson J., Savary L., Buclin T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin. Pharmacol. Ther., 64: 52-57, 1998.[Medline]
16. Leclercq I., Desago J-P., Horsman Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin. Pharmacol. Ther., 64: 144-149, 1998.[Medline]
17. Uematsu F., Kikuchi H., Ohmachi T., Sagami I., Motomiya M., Kamataki T., Komori M., Watanabe M. Two common RFLPs of the human CYP2E1 gene. Nucleic Acids Res., 19: 2803 1991.[Free Full Text]
18. Carrière V., Berthou F., Baird S., Belloc C., Beaune P., deWaziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6: 203-211, 1996.[Medline]
19. Powell H., Kitteringham N. R., Pirmohamed M., Smith D. A., Park B. K. Expression of cytochrome P4502E1 (CYP2E1) in human liver: assessment of mRNA, genotype and phenotype. Pharmacogenetics, 8: 411-421, 1998.[Medline]
20. Lucas D., Menez C., Girre C., Berthou F., Bodenez P., Joannet I., Hispard E., Bardou L-G., Menez J-F. Cytochrome P4502E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5: 298-304, 1995.[Medline]
21. Kim R. B., Yamazaki H., Chiba K., O’Shea D., Mimura M., Guengerich F. P., Ishizaki T., Shimada T., Wilkinson G. R. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J. Pharmacol. Exp. Ther., 279: 4-11, 1996.[Abstract/Free Full Text]
22. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P4502E1 gene. J. Biochem., 110: 559-565, 1991.[Abstract/Free Full Text]
23. Watanabe J., Hayashi S-I., Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. J. Biochem., 116: 321-326, 1994.[Abstract/Free Full Text]
24. Le Marchand L., Wilkens L. R., Kolonel L. N. Ethnic differences in the lung cancer risk associated with smoking. Cancer Epidemiol. Biomark. Prev., 1: 103-107, 1992.[Abstract]
25. Le Marchand L., Kolonel L. N. Cancer among Japanese migrants to Hawaii: gene-environment interactions. Rev. Epidemiol. Sante Publique, 40: 425-430, 1992.[Medline]
26. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A., Kanamaru R., Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. Cancer Res., 82: 254-256, 1991.[Medline]
27. Wu X., Shi H., Jiang H., Kemp B., Hong W. K., Delclos G. L., Spitz M. R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis (Lond.), 18: 967-973, 1997.[Abstract/Free Full Text]
28. Wu X. F., Amos C. I., Kemp B. L., Shi H. H., Jiang H., Wan Y., Spitz M. R. Cytochrome P450 2E1 DraI polymorphism in lung cancer in minority populations. Cancer Epidemiol. Biomark. Prev., 7: 13-18, 1998.[Abstract]
29. Le Marchand L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L. R., Lau A. F. Associations of CYP1A1, GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res., 58: 4858-4863, 1998.[Abstract/Free Full Text]
30. Le Marchand, L., Sivaraman, L., Pierce, L. M., Seifried, A., Lum, A., Franke, A. A., Custer, L. J., and Nerurkar, P. V. Gene-diet interactions and the high colorectal cancer risk of Japanese-Americans. Proceedings of the UICC Symposium on Familial Cancer and Prevention–Molecular Epidemiology: A New Strategy Towards Cancer Control. New York: John Wiley & Sons, in press, 1999.
31. United States Department of Agriculture. Nutrient Data Base for Standard Reference, Release 10. Bethesda, MD: Human Nutrition Information Service, USDA, 1992.
32. Willett W. C., Stampfer M. J. Total energy intake: implications for epidemiologic analyses. Am. J. Epidemiol., 124: 17-27, 1986.[Free Full Text]
33. Frye R. F., Adedoyin A., Mauro K., Matzke G. R., Branch R. A. Use of chlorzoxazone as in vivo probe of cytochrome P4502E1: choice of dose and phenotypic trait measure. J. Clin. Pharmacol., 38: 82-89, 1998.[Abstract]
34. O’Shea D., Kim R. B., Wilkinson G. R. Modulation of CYP2E1 activity by isoniazid in fast and slow acetylators. Br. J. Clin. Pharmacol., 43: 99-103, 1997.[Medline]
35. Nawaratne S., Brien J. E., Seeman E., Fabiny R., Zalcbery J., Cosolo W., Angus P., Morgan D. J. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br. J. Clin. Pharmacol., 46: 447-452, 1998.[Medline]
36. Yoo J-S. H., Smith T. J., Ning S. M., Lee M-J., Thomas P. E., Yang C. S. Modulation of the levels of cytochrome P450 in rat liver and lung by dietary lipid. Biochem. Pharmacol., 43: 2535-2542, 1992.[Medline]
37. Takahashi H., Johansson I., French S. W., Ingelman-Sundberg M. Effect of dietary fat composition on activities of the microsomal ethanol oxidizing system and ethanol-inducible cytochrome P450 (CYP2E1) in the liver of rats chronically fed ethanol. Pharmacol. Toxicol., 70: 347-352, 1992.[Medline]
38. Kato S., Shields P. G., Caporaso N. E., Hoover R. N., Trump B. F., Sugimura H., Weston A., Harris C. C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res., 52: 6712-6715, 1992.[Abstract/Free Full Text]
39. Stephens E. A., Taylor J. A., Kaplan N., Yang C-H., Hsieh L. L., Lucier G. W., Bell D. A. Ethnic variability in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4: 185-192, 1994.[Medline]
40. Hirvonen A., Husgafvel-Pursiainen K., Antilla S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis (Lond.), 14: 85-88, 1993.[Abstract/Free Full Text]
41. Persson I., Johansson I., Bergling H., Dahl M-L., Seidegard J., Rylander R., Rannug A., Hogberg J., Sundberg M. I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to incidence of lung cancer. FEBS Lett., 319: 207-211, 1993.[Medline]
42. Kato S., Shields P. G., Caporaso N. E., Sugimura H., Trivers G. E., Tucker M. A., Trump B. F., Weston A., Harris C. C. Analysis of cytochrome P4502E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomark. Prev., 3: 515-518, 1994.[Abstract]
43. El-Zein R. A., Zwischenberger J. B., Abdel-Rahman S. Z., Sankar A. B., Au W. W. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett., 112: 71-78, 1997.[Medline]
44. Yu M-W., Gladek-Yarborough A., Chiamprasert S., Santella R. M., Liaw Y-F., Chen C-J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology, 109: 1266-1273, 1995.[Medline]
45. Lin D-X., Tang Y-M., Peng Q., Lu S-X., Ambrosone C. B., Kadlubar F. F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol. Biomark. Prev., 7: 1013-1018, 1998.[Abstract]
46. London S. J., Daly A. K., Cooper J., Carpenter C. L., Navidi W. C., Ding L., Idle J. R. Lung cancer risk in relation to CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics, 6: 151-158, 1996.[Medline]
47. Watanabe J., Yang J-P., Eguchi H., Hayashi S., Imai K., Nakachi K., Kawajim K. An RsaI polymorphism in the CYP2E1 gene does not affect lung cancer risk in Japanese population. Jpn. J. Cancer Res., 86: 245-248, 1995.[Medline]
48. Block G., Patterson B., Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer, 18: 1-29, 1992.[Medline]
49. Wattenberg L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res., 52: 2085s-2091s, 1992.[Medline]
50. Yang C. S., Brady J. F., Hong J-Y. Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J., 6: 737-744, 1992.[Abstract]
51. Barcelo S., Gardiner J. M., Gescher A., Chipman J. K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis (Lond.), 17: 277-282, 1996.[Abstract/Free Full Text]
52. Ishizaki H., Brady J. F., Ning S. M., Yang C. S. Effect of phenethyl isothiocyanate on microsomal N-nitrosodimethyl amine metabolism and other monooxygenase activities. Xenobiotica, 20: 255-264, 1990.[Medline]
53. Brady J. F., Ishizaki H., Fukoto J. M., Lin M. C., Fadel A., Gapac J. M., Yang C. S. Inhibition of cytochrome P-4502E1 by diallylsulfide and its metabolites. Chem. Res. Toxicol., 4: 642-647, 1991.[Medline]
54. Kwak M. Y., Kim S. G., Kwak J. Y., Novak R. F., Kim N. D. Inhibition of cytochrome P4502E1 expression by organosulfur compounds allylsulfide allylmercaptan and allylmethylsulfide in rats. Biochem. Pharmacol., 47: 531-539, 1994.[Medline]
55. Shi S. T., Wang Z-T., Smith T. J., Hong J-Y., Chen W-F., Ho C-T., Yang C. S. Effects of green tea and black tea on 4-(methynitrosoamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation and lung tumorigenesis in A/J mice. Cancer Res., 54: 4641-4647, 1994.[Abstract/Free Full Text]
56. Kall M. A., Vang D., Clausen J. Effects of dietary broccoli or human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis (Lond.), 17: 793-799, 1996.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Morita, S. Tabata, O. Tajima, G. Yin, H. Abe, and S. Kono Genetic Polymorphisms of CYP2E1 and Risk of Colorectal Adenomas in the Self Defense Forces Health Study Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1800 - 1807. [Abstract] [Full Text] [PDF]

				D.-J. Kim, I.-G. Choi, B. L. Park, B.-C. Lee, B.-J. Ham, S. Yoon, J. S. Bae, H. S. Cheong, and H. D. Shin Major genetic components underlying alcoholism in Korean population Hum. Mol. Genet., March 15, 2008; 17(6): 854 - 858. [Abstract] [Full Text] [PDF]

				S. Kury, B. Buecher, S. Robiou-du-Pont, C. Scoul, V. Sebille, H. Colman, C. Le Houerou, T. Le Neel, J. Bourdon, R. Faroux, et al. Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1460 - 1467. [Abstract] [Full Text] [PDF]

				A. J. De Roos, L. S. Gold, S. Wang, P. Hartge, J. R. Cerhan, W. Cozen, M. Yeager, S. Chanock, N. Rothman, and R. K. Severson Metabolic Gene Variants and Risk of Non-Hodgkin's Lymphoma. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1647 - 1653. [Abstract] [Full Text] [PDF]

				K. Matsuo, K. Wakai, K. Hirose, H. Ito, T. Saito, and K. Tajima Alcohol Dehydrogenase 2 His47Arg Polymorphism Influences Drinking Habit Independently of Aldehyde Dehydrogenase 2 Glu487Lys Polymorphism: Analysis of 2,299 Japanese Subjects. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1009 - 1013. [Abstract] [Full Text] [PDF]

				K. Matsuo, K. Wakai, K. Hirose, H. Ito, T. Saito, T. Suzuki, T. Kato, T. Hirai, Y. Kanemitsu, H. Hamajima, et al. A gene-gene interaction between ALDH2 Glu487Lys and ADH2 His47Arg polymorphisms regarding the risk of colorectal cancer in Japan Carcinogenesis, May 1, 2006; 27(5): 1018 - 1023. [Abstract] [Full Text] [PDF]

				J. A. Milner Molecular Targets for Bioactive Food Components J. Nutr., September 1, 2004; 134(9): 2492S - 2498S. [Abstract] [Full Text] [PDF]

				A. J. De Roos, N. Rothman, P. D. Inskip, M. S. Linet, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, G. S. Pittman, and D. A. Bell Genetic Polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the Risk of Adult Brain Tumors Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 14 - 22. [Abstract] [Full Text] [PDF]

				L. Le Marchand, T. Donlon, A. Seifried, and L. R. Wilkens Red Meat Intake, CYP2E1 Genetic Polymorphisms, and Colorectal Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1019 - 1024. [Abstract] [Full Text] [PDF]

				C. Gao, T. Takezaki, J. Wu, Z. Li, J. Wang, J. Ding, Y. Liu, X. Hu, T. Xu, K. Tajima, et al. Interaction between Cytochrome P-450 2E1 Polymorphisms and Environmental Factors with Risk of Esophageal and Stomach Cancers in Chinese Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 29 - 34. [Abstract] [Full Text]

				G. D. Stoner and A. Gupta Etiology and chemoprevention of esophageal squamous cell carcinoma Carcinogenesis, November 1, 2001; 22(11): 1737 - 1746. [Abstract] [Full Text] [PDF]

				G D Loizou and J Cocker The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone Human and Experimental Toxicology, July 1, 2001; 20(7): 321 - 327. [Abstract] [PDF]

				I. N. Nishimoto, T. Hanaoka, H. Sugimura, K. Nagura, M. Ihara, X.-J. Li, T. Arai, G. S. Hamada, L. P. Kowalski, and S. Tsugane Cytochrome P450 2E1 Polymorphism in Gastric Cancer in Brazil: Case-Control Studies of Japanese Brazilians and Non-Japanese Brazilians Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 675 - 680. [Abstract] [Full Text]

				W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556. [Abstract] [Full Text]

				H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marchand, L. L. Articles by Wilkens, L. R. Search for Related Content PubMed PubMed Citation Articles by Marchand, L. L. Articles by Wilkens, L. R.